Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 32 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 59%

Novo Nordisk News

Ozempic,Wegovy,Semaglutide

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Here’s Why COVID Measures Like Masking And New Ones Like Safety Goggles Could Return If A Bird Flu Pandemic Is DeclaredOzempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but the company told Forbes it will only launch there once it could guarantee supplies for those already taking it asNovo said its blockbuster injectable Wegovy had been approved for...

Novo’s Global Media Relations Lead Camilla Louise Lyngsby declined to comment on potential Wegovy supply volume or a China launch date. In the face of stellar demand and plans to roll out in more territories, supplies of smaller Wegovy doses used by people beginning treatment have been severely restricted for months in the U.S. and as of writing the three lowest of five Wegovy doses areGiven the focus on ensuring access to higher doses for those already on the drugs, it is unclear whether Wegovy’s rollout in China will prolong or even worsen shortages in the U.S. and elsewhere for the lower starter doses.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in Aİ

Ai Ai Latest News, Ai Ai Headlines